Q2056 HCPCS code: Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Q2056 is the HCPCS Level II code for ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator51 — Drug or biological (priced per ASP/average sales price rules)
BETOS categoryO1D — Chemotherapy
Added2022-10-01
Last action effective2022-10-01

What changed for Q2056

Frequently asked questions

What is HCPCS code Q2056?

Q2056 is the HCPCS Level II code for ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. Short descriptor: "Ciltacabtagene car-pos t".

Does Medicare cover Q2056?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related Q20 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup